MedTrace Logo

Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats

NCT06491394 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-07-04

No results posted yet for this study

Summary

This study focuses on detecting the possible beneficial effect of Lactoferrin (Lf) administration on the kidney and the heart of glycerol-induced rhabdomyolysis (RM) in rats and its relation to ferroptosis and AMPK/Nrf2/ HO-1 signalling pathway. The main questions it aims to answer are:

1. Is Lf administration 30 min. before or after RM induction in rats beneficial to kidneys and heart?
2. When administered to glycerol-induced rats, does Lf act by upregulating the AMPK/Nrf2/ HO-1 signalling pathway and inhibiting ferroptosis?

Conditions

  • Rhabdomyolysis

Interventions

DRUG

Lactoferrin

an iron-binding protein

DIAGNOSTIC_TEST

iron

Iron in kidney and heart tissues

DIAGNOSTIC_TEST

MDA, TAC, and GSH

Oxidative stress levels in kidney and heart tissues

DIAGNOSTIC_TEST

Nrf2

Nrf2 expression in kidney and heart tissues

DIAGNOSTIC_TEST

AMPK

AMPK levels in heart and kidney tissues

DIAGNOSTIC_TEST

HO-1

HO-1 levels in kidney and heart tissues

DRUG

glycerin

GLY intramuscular injection for rhabdomyolysis induction

Sponsors & Collaborators

  • Aswan University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
10 Weeks
Max Age
12 Weeks
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-03-01
Completion
2025-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06491394 on ClinicalTrials.gov